Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer

摘要: Purpose As treatment options expand for metastatic colorectal cancer (mCRC), a blood marker with prognostic and predictive role could guide treatment. We tested the hypothesis that circulating tumor cells (CTCs) predict clinical outcome in patients mCRC. Patients Methods In prospective multicenter study, CTCs were enumerated peripheral of 430 mCRC at baseline after starting first-, second-, or third-line therapy. measured using an immunomagnetic separation technique. Results stratified into unfavorable favorable groups based on CTC levels three more less than CTCs/7.5 mL, respectively. compared had shorter median progression-free survival (PFS; 4.5 v 7.9 months; P = .0002) overall (OS; 9.4 18.5 < .0001). Differences persisted 1 to 2, 3 5, 6 12, 13 20 weeks Conversion CTC...